Nachrichten zur Orion Corp. Aktie

Orion Corporation: Jefferies sieht den Spitzenumsatz von Nubeqa nun 70 % höher bei 1,3 Mrd. Euro!

Die Orion Corporation hat sich auf Human- und Veterinärarzneimittel sowie pharmazeutische Wirkstoffe spezialisiert. Wichtige Wachstumstreiber sind u.a. das Krebsmedikament Darolutamid…

Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS22 August 2023 at 14.00 EEST ...…

QIX Dividenden Europa: Pharmahersteller Orion legt robusten 6-Monatsbericht vor

Die robusten Vorgaben der US-Börsen beflügeln am Mittwoch auch den QIX Dividenden Europa Index, der am Nachmittag leicht auf 12.630…

Orion Group Half-Year Financial Report 1–6/2023

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2023 17 JULY 2023 at 12:00 EEST...…

Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS7 July 2023 at 14.30 EEST Orion Corporation: Change in…

Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023

ORION CORPORATION PRESS RELEASE 4 July 2023 at 12.00 EEST...…

Orion invests EUR 30 million to increase production capacity in Finland

ORION CORPORATION PRESS RELEASE 28 June 2023 at 08.00 EEST...…

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Keskinäinen Eläkevakuutusyhtiö Ilmarinen)

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS21 JUNE 2023 at 17.00 EEST ...…

570 000 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE21 JUNE 2023 at 10.15…

Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki

ORION CORPORATION INVESTOR NEWS 25 MAY 2023 at 10.30 EEST ...…

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS3 MAY 2023 at 16.15 EEST ...…

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE28 APRIL 2023 at 11.30…

Orion publishes Interim Report for January–March 2023 on Thursday 27 April 2023

ORION CORPORATION PRESS RELEASE 13 April 2023 at 12.00 EEST...…

Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines

ORION CORPORATION PRESS RELEASE 30 March 2023 at 9.30 EEST...…

Orion and Bayer expand clinical development program for darolutamide in prostate cancer

ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate…

XFRA : DIVIDEND/INTEREST INFORMATION - 23.03.2023 - FI0009014377

Das Instrument OFK FI0009014377 ORION CORP. B EQUITY wird ex Dividende/Zinsen gehandelt am 23.03.2023 The instrument OFK FI0009014377 ORION CORP. B…

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE22 MARCH 2023 at 17.15…

Orion Corporation: Charman of the Nomination Committee changes

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE21 March 2023 at 17:45 EET…

Darolutamide approved for additional prostate cancer indication in China

ORION CORPORATION PRESS RELEASE 20 March 2023 at 09:00 EET Darolutamide approved for additional prostate cancer indication in China...…

Orion Corporation: Transfer of 149,798 own B shares on 1 March 2023

STOCK EXCHANGE RELEASE / CHANGES IN COMPANYS OWN SHARES ...…

Darolutamide receives EU approval for additional indication in prostate cancer

ORION CORPORATION PRESS RELEASE 1 March 2023 at 13:00 EET Darolutamide receives EU approval for additional indication in prostate cancer...…

Orion Group Financial Statement documents 2022, Corporate Governance Statement and Remuneration Report published

ORION CORPORATION STOCK EXCHANGE RELEASE / ANNUAL FINANCIAL REPORT 28 FEBRUARY 2023 at 9.30 EET ...…

Darolutamide receives approval for additional prostate cancer indication in Japan

ORION CORPORATION PRESS RELEASE 27 February 2023 at 9:00 EET Darolutamide receives approval for additional prostate cancer indication in Japan...…

Notice to the Annual General Meeting of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 9 FEBRUARY 2023 at 12:15 EET...…

Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer

ORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment…

Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023

ORION CORPORATION PRESS RELEASE 26 January 2023 at 12.00 EET...…

154,112 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE25 JANUARY 2023 at 9.00…

dpa-AFX ProFeed